>Azurocidin / CAP37 Protein & Antibody (AZU1, HBP)
Azurocidin / CAP37 Protein & Antibody (AZU1, HBP)
Cationic Antimicrobial Protein 37 / Heparin-Binding Protein
Azurocidin / CAP37 Products
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Azurocidin/CAP37||Human||Azurocidin/CAP37 Protein, Recombinant||10660-H08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human Azurocidin/CAP37||ELISA||Rabbit Polyclonal Antibody||10660-RP01|
|Human Azurocidin/CAP37||WB, ELISA||Rabbit Polyclonal Antibody (Antigen Affinity Purified)||10660-RP02|
Azurocidin / CAP37 Related Areas
Azurocidin / CAP37 Alternative Names
Azurocidin, CAP37, AZU1, AZU, HBP, AZAMP, HUMAZUR, NAZC [Homo sapiens]
Azurocidin / CAP37 Background
Azurocidin (AZU1), also known as heparin-binding protein (HBP) or cationic antimicrobial protein 37 (CAP37), is an azurophil granule antibiotic protein, with monocyte chemotactic and antibacterial activity. The Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. Azurocidin is a member of the serine protease family that includes Cathepsin G, neutrophil elastase (NE), and proteinase 3 (PR3), however, Azurocidin is not a serine proteinase since the active site serine and histidine residues are replaced. Neutrophils arriving first at sites of inflammation release Azurocidin, which acts in a paracrine fashion on endothelial cells causing the development of intercellular gaps and allowing leukocyte extravasation. It thus be regarded as a reasonable therapeutic target for a variety of inflammatory disease conditions.
Azurocidin / CAP37 Related Studies
- Lindmark A, et al. (1999) Characterization of the biosynthesis, processing, and sorting of human HBP/CAP37/azurocidin. J Leukoc Biol. 66(4): 634-43.
- Heinzelmann M, et al. (2001) Heparin binding protein (CAP37) differentially modulates endotoxin-induced cytokine production. Int J Surg Investig. 2(6): 457-66.
- Soehnlein O, et al. (2005) Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. J Immunol. 174(10): 6399-405.